Method of making inosine monophosphate derivatives and immunopot

Details Method of making inosine monophosphate derivatives and immunopot Method of making inosine monophosphate derivatives and immunopot

1995-04-21

1997-03-25

Kight, John

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 278, 536 267, C07H 1920, A61K 3170

Patent

active

056145047

ABSTRACT:
A method of making inosine-5'-monophosphate and its derivatives resistant to 5'-nucleotidase by chemically modifying inosine-5'-monophosphate to the formula: ##STR1## wherein R is selected from the group consisting of an alkyl, alkoxy and secondary amino compounds whereby inosine-5'-monophosphate biological activity is retained in vitro and extended to in vivo.

REFERENCES:
patent: 3560478 (1971-02-01), Myers
patent: 3575958 (1971-04-01), Nagasawa et al.
patent: 3728450 (1973-04-01), Gordon
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3839153 (1974-10-01), Schuurs et al.
patent: 3850578 (1974-11-01), McConnell
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3853987 (1974-12-01), Dreyer
patent: 3857940 (1974-12-01), Gordon
patent: 3867517 (1975-02-01), Ling
patent: 3879262 (1975-04-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein et al.
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio et al.
patent: 4221794 (1980-09-01), Simon et al.
patent: 4221909 (1980-09-01), Simon et al.
patent: 4221910 (1980-09-01), Giner-Sorolla
patent: 4340726 (1982-07-01), Simon et al.
patent: 4387226 (1983-06-01), Hadden et al.
patent: 4389395 (1983-06-01), Lerner et al.
patent: 4439196 (1984-03-01), Higuchi
patent: 4447224 (1984-05-01), DeCant, Jr. et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4457919 (1984-07-01), Simon et al.
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4510144 (1985-04-01), Hadden et al.
patent: 4512981 (1985-04-01), Gordon
patent: 4879219 (1989-11-01), Wands et al.
patent: 4950652 (1990-08-01), Carter
patent: 5011771 (1991-04-01), Bellet et al.
Specter et al., "New Approaches to Immunotherapy: Thymometric Drugs," Springer Sem. Immunopath., 8(4), 375-385 (1985); Chem. Abstr., 104(11), 81361j (1986); only CA Abstract provided.
Nichol et al., "Studies on Phosphate Binding Sites of Inosinic Acid Dehydrogenase and Adenylosuccinate Synthetase," Biochemistry, 6(4), 1008-1015 (1967).
Rosen et al., Dictionary of Immunology, M Stockton Press, New York, NY, 1989, p. 110.
W. S. Zielinski, "An Improved Synthetic Route to the .beta.-Hydroxy Esters of 5'-Nucleotides," Nucleic Acids Res., 3(7), 1769-1775 (1976).
Miller et al., "Models for the Interaction of Zn.sup.2+ with DNA. The Synthesis and X-ray Structural Characterization of Two Octahedral Zn Complexes with Monomethyl Phosphate Esters of 6-Oxopurine 5'-Monophosphate Nucleotides," J. Am. Chem. Soc., 107(4), 1048-1055 (1985).
H. G. Khorana, "Studies on Polynucleotides. VII. Approaches to the Marking of Ends Groups in Polynucleotide Chains: The Methylation of Phosphomonoester Groups," J. Am. Chem. Soc., 81, 4657-4660 (1959).
Hadden, "Immunostimulants," Trends in Pharmacology, 14, 169-174 (1993).
Hadden, "Immunotherapy of Human Immunodeficiency Virus Infection," Trends in Pharmacology, 12, 107-111 (1991).
Hadden et al., "Methyl Inosine Monophosphate (MIMP), A New Purine Immunomodulator for HIV Infection," Intl. J. Immunopharmacol., 13(Suppl. 1), 49-54 (1991).
Hadden et al.(II), "Methyl Inosine Monophosphate: A Potential Immunotherapeutic for Early Human Immunodeficiency Virus (HIV) Infection," Intl. J. Immunopharmacol., 14(4), 555-563 (1992).
Moffatt et al., "Nucleoside Polyphosphates. X. The Synthesis and Some Reactions of Nucleoside-5'-Phosphoromorpholidates and Related Compounds. Improved Methods for the Synthesis of Nucleoside-5'-Polyphosphates," J. Am. Chem. Soc., 83, 649-659 (1961).
R. S. Root-Bernstein(I), "AIDS Is More Than HIV: Part I," Genetic Engineering News, Sep. 1, 1992, pp. 4-6.
R. S. Root-Bernstein(II), "AIDS Is More Than HIV: Part II," Genetic Engineering News, Sep. 15, 1992, pp. 4-5.
Hadden et al.(III), "Methyl Inosine Monophosphate (MIMP), A New Purine Immunomodulator fo HIV Infection," International Journal of Immunopharmacology, 13(Suppl. 1), 49-54 (1991).
Alper et al., "Genetic prediction of nonresponse to hepatitis B vaccine" New Engl. J. Med., 321:708-712 (1989).
Benacerraf and McDevitt, "Histocompatibility-linked immune response genes" Science, 174:273-279 (1972).
Bogdan et al., "Macrophage deactivation by interleukin 10" J. Exp. Med., 174:1549-1555 (1991).
Byars and Allison, "Immunologic adjuvants: general properties, advantages and limitations" in Laboratory Methods in Immunology, 2:40-52 (1989).
Carelli et al., "Persistent enhancement of cell-mediated and antibody immune responses . . . " Infection and Immunity, pp. 312-314, (1981).
Carswell et al., "An endotoxin-induced serum factor that causes necrosis of tumors" Proc. Natl. Acad. Sci. USA 72:3666-3670 (1975).
Chakkalath et al., "Leishmania major-parasitized macrophages augment Th2-type T cell activation" J. Immunology, 153: 4378-4387 (1994).
Drews, "Novel immunological pathways to the treatment of infections" Infection, 22, No. 3, (1994 Fed. Proc., 29:684 (1970).
Fiorentino et al., "Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine . . . " J. Exp. Med., 170:2081-2095 (Dec. 1989).
Glasky et al., "Isoprinosine, a purine derivative . . . " In Proceedings of a Symposium and Workshop on Combined Immunodeficiency Disease . . . , Academic Press, Inc. New York, NY (1975).
Grossman and Cohen, "Immunization" in Basic and Clinical Immunology. (Seventh Edition) Appleton & Lange, Norwalk, CT pp. 725-726 (1991).
Haak-Frendscho et al., "Administration of anti-IL-4 monoclonal antibody 11B11 increases the resistance of mice . . . " J. Immunology, 148:3978-3985, (1992).
Hadden, "The action of immunopotentiators in vitro on lymphocyte and macrophage activation" in The Pharmacology of Immunoregulation, pp. 370-383 (1978).
Hadden, "Thymomimetic drugs" in Immunopharmacology, Raven Press, NY, p. 183 (1985).
Hadden, "Immunotherapy in the treatment of infectious diseases" in Proceedings of the Int'l Symposium on Immunological Adjuvants, Alan R. Liss, NY, pp. 337-349 (1987).
Hadden et al., "Effects of levamisole and imidazole on lymphocyte proliferation and cyclic nucleotide levels" Cell. Immun., pp. 98-103 (1975).
Hadden et al., "Levamisole and inosiplex: antiviral agents with immunopotentiating action" NY Acad. Sci., 284:139-152 (1976).
Hadden et al., "Purine analogs as immunodolulators" in Progress in Immunology IV. (Academic Press, NY) pp. 1393-1408 (1983).
Hadden et al., "Effects of T-cell growth factor (interleukin-II) and thymic hormones on prothymocytes and immature thymocytes" (1986); Lymphokine Res., 5, Supp. 1, S49-S54.
Hadden et al., "Methyl inosine monophosphate (MIMP)--A new purine immunomodulator" Int. J. Immunopharmacol., (abstract) 13:762 (1991a).
Hess et al., "Active immunization of homosexual men using a recombinant hepatitis B vaccine" J. Med. Virol., 29:229 (1989).
Khorana, "Studies on polynucleotides. VII. Approaches to the marking of end groups in polynucleotide chains . . . " J. Am. Chem. Soc., 81:4657-60 (1959).
MacDonald et al., "Requirement for a bacterial flora beore mice generate cells capable of mediating the delayed . . . " J. Immunol., 122:2624-2629 (1979).
Meuer et al., "Low does interleukin-2 induces immune response against HBsAg in immunodeficient nonresponders . . . " Lancet., 1-15 (1989).
Miller et al., "Models for the interaction of ZN with DNA. The synethesis and x-ray structural characterization . . . " J. Am. Chem. Soc., 107:1048-55 (1985).
Mosmann and Coffman, "Th1 and Th2 cells: differential patterns of lymphokine secretion lead to different functional properties" Ann. Rev. Immunol. 7:151-173 (1989).
Sad and Mosmann, "Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine . . . " J. Immunology, 3514-3522 (1994).
Saha et al., "Immunopotentiating activity of a nucleotide derivative, heptaminol AMP amidate (HAA) in mice . . . " Research Communications in Chemical Pathology and Pharmacology, 57(1):117-127 (Jul. 1987).
Saha et al., "Effect of heptaminol AMP amidate, a new nucleotide derivative, on In Vitro humoral immunity" Japan J. Pharmacol., 47:63-69 (1988).
Sandrin et

Affiliated with

Also associated with

Rating

Method of making inosine monophosphate derivatives and immunopot does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of making inosine monophosphate derivatives and immunopot, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of making inosine monophosphate derivatives and immunopot will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2203476